Efficacy of HIPRABOVIS® SOMNI/Lkt in front of a challenge infection with Mannheimia haemolytica in young calves

Home Knowledge Efficacy of HIPRABOVIS® SOMNI/Lkt in front of a challenge infection with Mannheimia haemolytica in young calves

Efficacy of HIPRABOVIS® SOMNI/Lkt in front of a challenge infection with Mannheimia haemolytica in young calves

The aim of this study was to demonstrate the protection conferred in calves by HIPRABOVIS® SOMNI/Lkt through challenge infection with Mannheimia haemolytica, the most virulent and commonly isolated bacterial pathogen in BRD causing severe fibrinonecrotizing pleuropneumonia in lungs (Griffin D. 2010).

About this article

Authors

Foix, A.; Relancio B., Casademunt, S.; March, R.

Summary

HIPRABOVIS® SOMNI/Lkt proved to be effective in front of an experimental infection with M. haemolytica presenting significantly fewer respiratory problems and reducing percentage and severity of pneumonic lesions. Therefore, the clinical signs and economic impact associated with the pathogenesis of this bacterial agent could be reduced using this vaccine.

Related products

Share this on